However, for patients younger than 55 years, or those with a history of lower-grade glioma and/or tumors showing immunohistochemical loss of nuclear ATRX expression, negative IDH1 p.R132H immunostaining should be followed by DNA sequencing to identify less common IDH1 or IDH2 mutations. This evidence concerns the gene IDH2 and glioma.